WALTHAM, Mass., Sept. 21,
2021 /PRNewswire/ -- CorEvitas, LLC, the gold-standard
leader in longitudinal real-world data in autoimmune and
inflammatory diseases, today announced that it has expanded its
engagement with Inovalon's (NASDAQ: INOV) life sciences
business unit specializing in data-driven healthcare analytics
and strategic advisory services, to provide a holistic view of
patients with rheumatoid arthritis or psoriasis.
In conjunction with CorEvitas' granular clinical data on
validated physician assessments and patient-reported outcomes, this
collaboration focuses on rheumatoid arthritis and psoriasis and
highlights one of many critical chronic condition-focused use cases
of Inovalon's MORE² Registry®
dataset, which today provides the healthcare marketplace insight
into tens millions of patients suffering from key chronic
conditions that contribute to poor clinical outcomes and increased
healthcare costs in the United
States.
"The healthcare marketplace, especially life sciences companies
and health plans, have been eager to make more definitive
connections between clinical measures, patient adherence,
laboratory values, healthcare resource utilization, and economic
outcomes along the patient journey," said John E. Linnehan, practice director of
Inovalon's health economics and advanced analytics team. "We are
excited to collaborate with CorEvitas to accelerate these insights
with an initial focus on rheumatoid arthritis and psoriasis."
With a comprehensive snapshot of individual patients with either
rheumatoid arthritis or psoriasis, unique from any one given
dataset, CorEvitas' experts are presented with the opportunity for
real-world and longitudinal assessment of the dynamics between
demographics, clinical characteristics, functional status,
patient-reported outcome measures, laboratory values, healthcare
resource utilization, and economic outcomes. Insights made
possible through these analytics can advance clinical development,
inform trial design and recruitment, substantiate value narratives,
and inform patient-specific intervention plans.
Raymond Hill, Chairman and Chief
Executive Officer for CorEvitas, noted, "As an organization, we
recognize the immeasurable value of understanding the whole
patient. By furthering our collaboration with Inovalon, we can
leverage the data-driven insights that provide integrated and
actionable insights for the patient. This symbiotic expansion of
real-world evidence will ultimately advance healthcare to its next
level."
CorEvitas collects comprehensive, prospective and structured
gold-standard data that provides unmatched clinical depth and
granularity. Data collected from over 475 sites in the U.S.,
Canada, and Japan make CorEvitas the largest network of
real-world investigators contributing prospective data for patients
with autoimmune and inflammatory conditions.
"We are excited to be able to provide our subscriber base with
these expanded use cases," said Leslie
Harrold, MD, MPH, Chief Scientific Officer of CorEvitas. "So
much real-world data is siloed. By connecting data, we can
understand so much more about our patients and their needs –
ultimately improving care paradigms."
About CorEvitasSM
CorEvitas is the built-for-purpose gold-standard provider
of real-world evidence. Through syndicated registry data and
analytic services, CorEvitas helps biopharmaceutical companies
demonstrate the value of their products to clinicians, patients,
payers, and regulators. CorEvitas operates eight major autoimmune
and inflammatory registries across the U.S., Canada, and Japan, collecting data from nearly 500
participating investigator sites. In addition to supporting
hundreds of manuscripts and abstracts, CorEvitas has supported post
approval safety commitments for multiple newly approved treatments
in autoimmune diseases for both U.S. and European regulators.
CorEvitas is headquartered in Waltham,
MA. Its subsidiary, HealthiVibe, complements and strengthens
the company's strong presence in disease registries by providing
market-leading expertise in supporting innovative, evidence-based
patient engagement initiatives across the product lifecycle. The
HealthUnlocked technology platform hosts over 1.4 million patients
in hundreds of condition-specific communities and significantly
expands the scope of patient experiential data. Through Health iQ,
CorEvitas has access to a broad range of UK and international
datasets across primary and secondary care, as well as deep
relationships with the NHS and leading UK academic institutions.
Vestrum Health, a leader in data analytics of retinal practice
Electronic Health Records, provides insightful views of retinal
diseases across the drug life cycle. CorEvitas is a portfolio
company of Audax Private Equity.
About Inovalon
Inovalon is a leading provider of
cloud-based platforms empowering data-driven healthcare. Through
the Inovalon ONE® Platform, Inovalon brings to
the marketplace a national-scale capability to interconnect with
the healthcare ecosystem, aggregate and analyze data in real time,
and empower the application of resulting insights to drive
meaningful impact at the point of care. Leveraging its Platform,
unparalleled proprietary datasets, and industry-leading subject
matter expertise, Inovalon enables better care, efficiency, and
financial performance across the healthcare ecosystem. From health
plans and provider organizations, to pharmaceutical, medical
device, and diagnostics companies, Inovalon's unique achievement of
value is delivered through the effective progression of "Turning
Data into Insight, and Insight into Action®."
Supporting thousands of customers, including all 25 of the top 25
U.S. health plans, all 25 of the top 25 global pharma companies, 24
of the top 25 U.S. healthcare provider systems, and many of the
leading pharmacy organizations, device manufacturers, and other
healthcare industry constituents, Inovalon's technology platforms
and analytics are informed by data pertaining to more than one
million physicians, 584,000 clinical facilities, 338 million
Americans, and 63 billion medical events. For more information,
visit www.inovalon.com.
CONTACT INFORMATION:
CorEvitas,
LLC
Erem
Latif
(508)
408-5529
elatif@corevitas.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/corevitas-and-inovalon-leverage-advanced-analytics-to-deliver-a-holistic-view-of-the-patient-301380615.html
SOURCE CorEvitas, LLC